MTOR and subependymal giant cell astrocytoma: Subsequently, its structural analogues (rapalogs) such as RAD001 (everolimus) and CCI-779 (temsirolimus) with reduced immunosuppresive effects and improved pharmacological properties are designed and have been approved by FDA for the treatment of subependymal giant cell astrocytoma (SEGA) or renal cell carcinoma, suggesting a potential of mTOR inhibitors in cancer treatment [84, 85].